ATE244234T1 - Substituierte imidazole zur behandlung von entzündlichen krankheiten - Google Patents

Substituierte imidazole zur behandlung von entzündlichen krankheiten

Info

Publication number
ATE244234T1
ATE244234T1 AT98918463T AT98918463T ATE244234T1 AT E244234 T1 ATE244234 T1 AT E244234T1 AT 98918463 T AT98918463 T AT 98918463T AT 98918463 T AT98918463 T AT 98918463T AT E244234 T1 ATE244234 T1 AT E244234T1
Authority
AT
Austria
Prior art keywords
treatment
inflammatory diseases
substituted imidazoles
imidazoles
substituted
Prior art date
Application number
AT98918463T
Other languages
English (en)
Inventor
Scott A Beers
Elizabeth Malloy
Michael P Wachter
Wei Wu
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Application granted granted Critical
Publication of ATE244234T1 publication Critical patent/ATE244234T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT98918463T 1997-04-24 1998-04-17 Substituierte imidazole zur behandlung von entzündlichen krankheiten ATE244234T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4425297P 1997-04-24 1997-04-24
PCT/US1998/007910 WO1998047892A1 (en) 1997-04-24 1998-04-17 Substituted imidazoles useful in the treatment of inflammatory diseases

Publications (1)

Publication Number Publication Date
ATE244234T1 true ATE244234T1 (de) 2003-07-15

Family

ID=21931339

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98918463T ATE244234T1 (de) 1997-04-24 1998-04-17 Substituierte imidazole zur behandlung von entzündlichen krankheiten

Country Status (24)

Country Link
US (3) US5965583A (de)
EP (1) EP1028954B1 (de)
JP (1) JP2001522357A (de)
KR (1) KR100568438B1 (de)
CN (1) CN1211381C (de)
AR (1) AR012594A1 (de)
AT (1) ATE244234T1 (de)
AU (1) AU7138298A (de)
BR (1) BR9808998A (de)
CA (1) CA2297176A1 (de)
DE (1) DE69816109T2 (de)
DK (1) DK1028954T3 (de)
ES (1) ES2202840T3 (de)
HU (1) HUP0002842A3 (de)
IL (1) IL132318A0 (de)
NO (1) NO318937B1 (de)
NZ (1) NZ500447A (de)
PL (1) PL191111B1 (de)
PT (1) PT1028954E (de)
RU (1) RU2222534C2 (de)
TR (1) TR199902622T2 (de)
UA (1) UA65572C2 (de)
WO (1) WO1998047892A1 (de)
ZA (1) ZA983451B (de)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
EP0956018A4 (de) 1996-08-21 2000-01-12 Smithkline Beecham Corp Imidazolverbindungen, deren zusammensetzungen und verwendung
AU7138298A (en) 1997-04-24 1998-11-13 Ortho-Mcneil Corporation, Inc. Substituted imidazoles useful in the treatment of inflammatory diseases
AU7966198A (en) 1997-06-13 1998-12-30 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
US6610695B1 (en) 1997-06-19 2003-08-26 Smithkline Beecham Corporation Aryloxy substituted pyrimidine imidazole compounds
GB9713726D0 (en) 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
US6489325B1 (en) 1998-07-01 2002-12-03 Smithkline Beecham Corporation Substituted imidazole compounds
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
CA2295762A1 (en) 1997-07-02 1999-01-14 Ravi Shanker Garigipati Novel cycloalkyl substituted imidazoles
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
EP1041989A4 (de) 1997-10-08 2002-11-20 Smithkline Beecham Corp Neue cycloalkenyl substituierte verbindungen
WO1999021555A2 (en) * 1997-10-27 1999-05-06 Takeda Chemical Industries, Ltd. Adenosine a3 receptor antagonists
WO1999032121A1 (en) 1997-12-19 1999-07-01 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
KR20010025087A (ko) 1998-05-22 2001-03-26 스튜어트 알. 수터 신규한 2-알킬 치환된 이미다졸 화합물
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
US6207687B1 (en) 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
JP2002526388A (ja) 1998-10-07 2002-08-20 スミスクライン・ビーチャム・コーポレイション 発作を管理するための新規な処置
EP1126852B1 (de) 1998-11-04 2004-01-21 SmithKline Beecham Corporation Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine
WO2000057913A1 (fr) 1999-03-25 2000-10-05 Welfide Corporation Prophylaxies/remedes pour la pneumonie interstitielle et la fibrose pulmonaire
US6291457B1 (en) * 1999-07-01 2001-09-18 Merck & Co., Inc. Compounds having cytokine inhibitory activity
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
DE60111417T2 (de) 2000-10-18 2006-03-16 Ortho-Mcneil Pharmaceutical, Inc. Substituierte imidazole, die sich für die behandlung entzündlicher krankheiten eignen
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
EP1506966A3 (de) * 2001-03-26 2005-09-14 Ortho-Mcneil Pharmaceutical, Inc. Verfahren zur Herstellung von tetrasubstituierte imidazolderivaten sowie deren neue Kristalline Strukturen
CZ20032871A3 (cs) * 2001-03-26 2004-08-18 Ortho@Mcneilápharmaceuticalźáinc Způsob přípravy tetrasubstituovaných derivátů imidazolu a jejich nových krystalických struktur
GB0112348D0 (en) * 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
JP4212470B2 (ja) 2001-06-26 2009-01-21 アムジェン フレモント インク． Ｏｐｇｌへの抗体
WO2003014309A2 (en) * 2001-08-07 2003-02-20 Immunex Corporation Interleukin-1 receptors in the treatment of diseases
KR20020009532A (ko) * 2001-11-13 2002-02-01 (주)쎌믹스 류코트리엔 합성 억제용 조성물
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
HRP20020453A2 (en) 2002-05-23 2003-12-31 Pliva D D 1,3-diaza-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediate for preparation thereof
AU2003245989A1 (en) 2002-07-09 2004-01-23 Boehringer Ingelheim Pharma Gmbh And Co. Kg Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
EP1531674B1 (de) 2002-08-19 2014-06-18 Lorus Therapeutics Inc. 2,4,5-trisubstituierte imidazole und deren verwendung als antimikrobielle wirkstoffe
UA80295C2 (en) 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
ATE549033T1 (de) 2002-09-06 2012-03-15 Amgen Inc Therapeutischer menschlicher monoklonaler anti-il-1r1-antikörper
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
WO2004078116A2 (en) * 2003-03-03 2004-09-16 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7429378B2 (en) * 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
US7344716B2 (en) * 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US20040229878A1 (en) * 2003-05-13 2004-11-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of P38 kinase
US8273347B2 (en) 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US7553827B2 (en) * 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
WO2005000405A2 (en) * 2003-06-06 2005-01-06 The Trustees Of The University Of Pennsylvania P38 kinase inhibitor compositions and methods of use
US8361467B2 (en) * 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
JP5095216B2 (ja) 2003-11-14 2012-12-12 ローラス セラピューティクス インコーポレーテッド アリールイミダゾールおよびその抗癌剤としての使用
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
US7250434B2 (en) 2003-12-22 2007-07-31 Janssen Pharmaceutica N.V. CCK-1 receptor modulators
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
US20080119498A1 (en) * 2004-12-06 2008-05-22 Masatomo Kato Therapeutic Agent for Pruritus Comprising P38 Map Kinase Inhibitor as the Active Ingredient
US8017395B2 (en) 2004-12-17 2011-09-13 Lifescan, Inc. Seeding cells on porous supports
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1676574A3 (de) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Verfahren zur Förderung des Überlebens von Zell- und Gewebe-Transplantaten
CA2611032C (en) * 2005-05-25 2012-01-17 Genesense Technologies Inc. 2-indolyl imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer
PL1888123T3 (pl) 2005-06-08 2013-06-28 Janssen Biotech Inc Terapia komórkowa chorób degeneracyjnych oka
CA2635813C (en) * 2006-01-31 2014-01-07 Array Biopharma, Inc. Urea derivatives as kinase inhibitors and methods of use thereof
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
EP1992344A1 (de) 2007-05-18 2008-11-19 Institut Curie P38 Alpha als therapeutisches Target für Erkrankungen, die mit einer FGFR3- Mutation assoziiert sind
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
KR101617243B1 (ko) 2007-07-31 2016-05-02 라이프스캔, 인코포레이티드 인간 배아 줄기 세포의 분화
MX2010005805A (es) 2007-11-27 2010-06-09 Lifescan Inc Diferenciacion de celulas madre embrionarias humanas.
US8986696B2 (en) * 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
US20090162351A1 (en) * 2007-12-21 2009-06-25 Depuy Spine, Inc. Transdiscal administration of inhibitors of p38 MAP kinase
JP5733986B2 (ja) 2008-02-21 2015-06-10 ヤンセン バイオテツク，インコーポレーテツド 細胞の付着、培養、及び剥離のための方法、表面改質されたプレート、並びに組成物
EP2111861A1 (de) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Zusammensetzungen von Phosphodiesterase-IV-Hemmern
US8623648B2 (en) * 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
KR101651661B1 (ko) 2008-06-30 2016-08-26 얀센 바이오테크 인코포레이티드 만능 줄기 세포의 분화
US9012218B2 (en) 2008-10-31 2015-04-21 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
PL2346988T3 (pl) 2008-10-31 2017-10-31 Janssen Biotech Inc Różnicowanie ludzkich zarodkowych komórek macierzystych do linii endokrynnej trzustki
JP5719305B2 (ja) 2008-11-20 2015-05-13 ヤンセン バイオテツク，インコーポレーテツド 平面支持体上での細胞付着及び培養のための方法及び組成物
KR101774546B1 (ko) 2008-11-20 2017-09-04 얀센 바이오테크 인코포레이티드 마이크로-캐리어 상의 만능 줄기 세포 배양
US8334287B2 (en) * 2009-07-17 2012-12-18 Hoffmann-La Roche Inc. Imidazoles
CN102482643B (zh) 2009-07-20 2016-06-29 詹森生物科技公司 人胚胎干细胞的分化
EP2456859A4 (de) 2009-07-20 2015-03-18 Janssen Biotech Inc Differenzierung menschlicher embryonischer stammzellen
EP2456858B1 (de) 2009-07-20 2018-08-29 Janssen Biotech, Inc. Differenzierung menschlicher embryonischer stammzellen
CN102741395B (zh) 2009-12-23 2016-03-16 詹森生物科技公司 人胚胎干细胞的分化
EP2516626B1 (de) 2009-12-23 2017-05-10 Janssen Biotech, Inc. Differenzierung menschlicher embryonischer stammzellen
JP6013196B2 (ja) 2010-03-01 2016-10-25 ヤンセン バイオテツク，インコーポレーテツド 多能性幹細胞から誘導した細胞を精製するための方法
AU2011250912A1 (en) 2010-05-12 2012-11-22 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
CA2809300A1 (en) 2010-08-31 2012-03-08 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
EP2611907B1 (de) 2010-08-31 2016-05-04 Janssen Biotech, Inc. Differenzierung pluripotenter stammzellen
AU2011296382B2 (en) 2010-08-31 2016-04-14 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
SG10201608914WA (en) 2011-12-22 2016-12-29 Janssen Biotech Inc Differentiation of human embryonic stem cells into single hormonal insulin positive cells
JP6218229B2 (ja) 2011-12-28 2017-10-25 京都府公立大学法人 角膜内皮細胞の培養正常化
KR20140131999A (ko) 2012-03-07 2014-11-14 얀센 바이오테크 인코포레이티드 만능 줄기 세포의 증폭 및 유지를 위한 한정 배지
US10066210B2 (en) 2012-06-08 2018-09-04 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells
BR112015015714A2 (pt) 2012-12-31 2017-07-11 Janssen Biotech Inc suspensão e aglomeração de células pluripotentes humanas para diferenciação em célu-las endócrinas pancreáticas
SG10201709338RA (en) 2012-12-31 2017-12-28 Janssen Biotech Inc Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
KR101942769B1 (ko) 2012-12-31 2019-01-28 얀센 바이오테크 인코포레이티드 Hb9 조절제를 사용하는 인간 배아 줄기세포의 췌장 내분비 세포로의 분화
WO2014153464A2 (en) 2013-03-20 2014-09-25 Lorus Therapeutics Inc. 2-substituted imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer
KR20160058960A (ko) 2013-10-04 2016-05-25 압토스 바이오사이언시스 인코포레이티드 암을 치료하기 위한 조성물과 방법
JP6730701B2 (ja) 2013-11-14 2020-07-29 学校法人同志社 細胞増殖促進または細胞障害抑制による角膜内皮治療薬
CN116942832A (zh) 2014-05-16 2023-10-27 归属疗法有限公司 抗流感病毒和金黄色葡萄球菌合并感染的新型抗感染策略
CN117821369A (zh) 2014-05-16 2024-04-05 詹森生物科技公司 小分子增强胰腺内分泌细胞中的mafa表达的用途
US20170266173A1 (en) 2014-08-25 2017-09-21 Bing Hui Wang Mapk inhibitors
MA45479A (fr) 2016-04-14 2019-02-20 Janssen Biotech Inc Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
HRP20221196T1 (hr) 2017-10-05 2022-12-09 Fulcrum Therapeutics, Inc. Inhibitori p38 kinaze smanjuju ekspresiju dux4 i nizvodnih gena u cilju liječenja fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
EP3703685A4 (de) 2017-10-30 2021-07-28 Aptose Biosciences Inc. Arylimidazole zur behandlung von krebs
EP3836954A1 (de) 2018-08-13 2021-06-23 Iltoo Pharma Kombination von interleukin-2 mit einem interleukin-1-inhibitor, konjugate und therapeutische verwendungen davon
US11814404B2 (en) 2020-07-20 2023-11-14 Annexon, Inc. Inhibitors of complement factors and uses thereof
WO2023280911A1 (en) 2021-07-06 2023-01-12 Westfälische Wilhelms-Universität Münster P38-inhibitors for the treatment of coronavirus infections and/or covid-19 cytokine storm
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2963572D1 (en) * 1978-04-11 1982-10-21 Ciba Geigy Ag Mercapto-imidazole derivatives, their preparation, mercapto-imidazole derivatives for the treatment of inflammatory diseases and their pharmaceutical compositions
DD201677A5 (de) * 1980-07-25 1983-08-03 Ciba Geigy Verfahren zur herstellung von trisubstituierten imidazolderivaten
US4503065A (en) * 1982-08-03 1985-03-05 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl 1-2-halo imidazoles
US5633377A (en) * 1990-12-28 1997-05-27 Neurogen Corporation 4-piperidino- and piperazinomethyl-2-cyclohexyl imidazole derivatives; dopamine receptor subtype specific ligands
IL104369A0 (en) * 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
US5593992A (en) 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
AU7138298A (en) 1997-04-24 1998-11-13 Ortho-Mcneil Corporation, Inc. Substituted imidazoles useful in the treatment of inflammatory diseases

Also Published As

Publication number Publication date
AR012594A1 (es) 2000-11-08
PL191111B1 (pl) 2006-03-31
NO318937B1 (no) 2005-05-30
IL132318A0 (en) 2001-03-19
US6214830B1 (en) 2001-04-10
DE69816109T2 (de) 2004-04-22
CN1211381C (zh) 2005-07-20
JP2001522357A (ja) 2001-11-13
KR100568438B1 (ko) 2006-04-07
ES2202840T3 (es) 2004-04-01
CN1253558A (zh) 2000-05-17
BR9808998A (pt) 2000-08-08
DE69816109D1 (de) 2003-08-07
PL336758A1 (en) 2000-07-17
EP1028954A1 (de) 2000-08-23
RU2222534C2 (ru) 2004-01-27
KR20010020204A (ko) 2001-03-15
HUP0002842A2 (hu) 2001-06-28
AU7138298A (en) 1998-11-13
NZ500447A (en) 2001-09-28
WO1998047892A1 (en) 1998-10-29
EP1028954B1 (de) 2003-07-02
US5965583A (en) 1999-10-12
PT1028954E (pt) 2003-11-28
HUP0002842A3 (en) 2002-01-28
US6521655B1 (en) 2003-02-18
NO995095L (no) 1999-12-09
DK1028954T3 (da) 2003-10-27
NO995095D0 (no) 1999-10-19
UA65572C2 (en) 2004-04-15
CA2297176A1 (en) 1998-10-29
ZA983451B (en) 1999-10-25
TR199902622T2 (xx) 2000-05-22

Similar Documents

Publication Publication Date Title
ATE244234T1 (de) Substituierte imidazole zur behandlung von entzündlichen krankheiten
DE69724016D1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen erkrankungen der atemwege
ATE235481T1 (de) Substituierte benzopyranderivate zur behandlung von entzündungen
NO20012995L (no) Forbindelser nyttige for behandling av inflammatoriske sykdommer
ATE231724T1 (de) Kombinationstherapie für die behandlung von psychosen
ATE262331T1 (de) Heterocyclische vinylether zur behandlung neurologischer krankheiten
ATE371457T1 (de) Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
DE69734513D1 (de) Phenylamino-substituierte triicyclische derivate zur behandlung hyperproliferativer krankheiten
DE59711321D1 (de) Neue substituierte pyrazolderivate zur behandlung von herzkreislauferkrankungen
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE50009504D1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
DE59608738D1 (de) Verwendung von epinastin für die behandlung von schmerzen
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE69807466D1 (de) Triptolid-derivate nützlich zur behandlung von autoimmunkrankheiten
DE69737067D1 (de) Vakzine zur behandlung von mycosen
DE69822297D1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
DE69729735D1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE60021252D1 (de) Antikonvulsiva zur behandlung von autismus
DE59704933D1 (de) Verwendung von PHMB zur Behandlung von Tumorerkrankungen
DE69834937D1 (de) Antibiotika zur behandlung von magengeschwuren
DE60005685D1 (de) Oxazinocarbazole zur behandlung von cns-erkrankungen
DE69806062T2 (de) Kombinationstherapie zur behandlung von aids
ATE226440T1 (de) Zusammensetzung zur behandlung von psoriasis
IS2153B (is) S-nítrósóþíól til meðferðar við blóðrásartruflunum
ATE261965T1 (de) Bispidin-derivate zur behandlung von herzarrhythmien

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1028954

Country of ref document: EP

REN Ceased due to non-payment of the annual fee